Physician profile
Benjamin R Marks
NPI 1407086317
$8,975.42
in general payments reported to CMS, 2019-2025
21 companies · $2,133 in 2025
The $2,133 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $54.10 · 2021: $712 · 2022: $1,017 · 2023: $2,503 · 2024: $1,965 · 2025: $2,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,159 · Education: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,158.56 |
| Education | $442.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,206.12 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Arcutis Biotherapeutics, INC. | $1,951.76 | 2023-2025 | Zoryve |
| Abbvie INC. | $741.55 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $735.33 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $697.38 | 2019-2025 | |
| Lilly USA, LLC | $677.38 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $486.69 | 2019-2024 | |
| Genzyme Corporation | $347.41 | 2023-2024 | |
| Journey Medical Corporation | $260.33 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $239.89 | 2022-2024 | Ilumya, Winlevi |
| Ucb, INC. | $147.01 | 2025 | Bimzelx |
| Dermira, INC. | $134.65 | 2020-2021 | |
| Taro Pharmaceuticals USA, INC. | $78.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Incyte Corporation | $44.47 | 2022-2025 | Opzelura |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $40.10 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.59 | 2024 | Cabtreo |
| Almirall LLC | $27.89 | 2021 | |
| Revance Therapeutics, INC. | $22.14 | 2024 | Daxxify |
| Organogenesis INC. | $13.31 | 2023 | Puraply |
| Galderma Laboratories, L.P. | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.